PURPOSE OF REVIEW: Options for prostate cancer management are rapidly expanding. The recent advent of MRI technology has led to guided prostate biopsies by radiologists working in-bore or by urologists using MR/US fusion technology. The resulting tumor visualization now provides the option of focal therapy. Currently available are highly directed energies - focused ultrasound (HIFU), cryotherapy, and laser - all offering the hope of curing prostate cancer with few side effects. RECENT FINDINGS: MRI now enables visualization of many prostate cancers. MR/US fusion biopsy makes possible the targeted biopsy of suspicious lesions efficiently in the urology clinic. Several fusion devices are now commercially available. Focal therapy, a derivative of targeted biopsy, is reshaping the approach to treatment of some prostate cancers. Focal laser ablation, originally done in the MRI gantry (in-bore), promises to soon become feasible in a clinic setting (out-of-bore) under local anesthesia. Other focal therapy options, including HIFU and cryotherapy, are currently available. Herein are summarized outcomes data on focal therapy modalities. SUMMARY: MRI-guided biopsy is optimizing prostate cancer diagnosis. Focal therapy, an outgrowth of guided biopsy, promises to become a well tolerated and effective approach to treating many men with prostate cancer while minimizing the risks of incontinence and impotence from radical treatment.
PURPOSE OF REVIEW: Options for prostate cancer management are rapidly expanding. The recent advent of MRI technology has led to guided prostate biopsies by radiologists working in-bore or by urologists using MR/US fusion technology. The resulting tumor visualization now provides the option of focal therapy. Currently available are highly directed energies - focused ultrasound (HIFU), cryotherapy, and laser - all offering the hope of curing prostate cancer with few side effects. RECENT FINDINGS: MRI now enables visualization of many prostate cancers. MR/US fusion biopsy makes possible the targeted biopsy of suspicious lesions efficiently in the urology clinic. Several fusion devices are now commercially available. Focal therapy, a derivative of targeted biopsy, is reshaping the approach to treatment of some prostate cancers. Focal laser ablation, originally done in the MRI gantry (in-bore), promises to soon become feasible in a clinic setting (out-of-bore) under local anesthesia. Other focal therapy options, including HIFU and cryotherapy, are currently available. Herein are summarized outcomes data on focal therapy modalities. SUMMARY: MRI-guided biopsy is optimizing prostate cancer diagnosis. Focal therapy, an outgrowth of guided biopsy, promises to become a well tolerated and effective approach to treating many men with prostate cancer while minimizing the risks of incontinence and impotence from radical treatment.
Authors: Amine B El Fegoun; Eric Barret; Dominique Prapotnich; Shawn Soon; Xavier Cathelineau; François Rozet; Marc Galiano; Rafael Sanchez-Salas; Guy Vallancien Journal: Int Braz J Urol Date: 2011 Mar-Apr Impact factor: 1.541
Authors: Melissa H Mendez; Niccolo Maria Passoni; Julio Pow-Sang; J Stephen Jones; Thomas J Polascik Journal: J Endourol Date: 2015-07-13 Impact factor: 2.942
Authors: Aytekin Oto; Ila Sethi; Gregory Karczmar; Roger McNichols; Marko K Ivancevic; Walter M Stadler; Sydeaka Watson; Scott Eggener Journal: Radiology Date: 2013-02-25 Impact factor: 11.105
Authors: R van Velthoven; F Aoun; Q Marcelis; S Albisinni; M Zanaty; M Lemort; A Peltier; K Limani Journal: Prostate Cancer Prostatic Dis Date: 2015-11-24 Impact factor: 5.554
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Christine H Feng; Christopher C Conlin; Kanha Batra; Ana E Rodríguez-Soto; Roshan Karunamuni; Aaron Simon; Joshua Kuperman; Rebecca Rakow-Penner; Michael E Hahn; Anders M Dale; Tyler M Seibert Journal: J Magn Reson Imaging Date: 2021-03-31 Impact factor: 5.119